Introduction
Madrigal Pharmaceuticals (MDGL), Galmed Pharmaceuticals (GLMD), and Galectin Therapeutics (GALT) are small or mid-cap clinical stage biopharmas with a common unifying clinical goal of developing effective therapeutics for NASH disease. Madrigal (Resmetirom), Galmed (Aramchol), and Galectin (Belapectin) are the focus of this article because of their diverse pharmacological targets and clinical effects in NASH. Moreover, these Phase 3 drug assets are the next wave of potential NASH therapeutics seeking NDA approval in the next 3-4 years.
NASH is a two-phase silent/symptomless disease with a progressive, incompletely understood pathophysiology